Form 4: QuidelOrtho Director John R. Chiminski Increases Equity Holdings Through Restricted Stock Unit Grants

QuidelOrtho Corp Director John R. Chiminski reported the acquisition of 9,755 restricted stock units (RSUs) through equity grants and conversion of cash compensation, aligning his interests with shareholders.

Summary

• John R. Chiminski, a Director of QuidelOrtho Corp (QDEL), reported transactions involving restricted stock units (RSUs) on May 29, 2025.
• He acquired 6,829 Restricted Stock Units as an equity grant, which are scheduled to vest on May 29, 2026.
• An additional 2,439 Restricted Stock Units were acquired, converted from cash payments for retainer and Board of Director service-related fees under a deferred compensation program for non-employee directors.
• The vesting schedule for the converted RSUs is staggered: 609 shares vested on May 29, 2025; 610 shares will vest on August 29, 2025; 610 shares will vest on November 29, 2025; and 610 shares will vest on February 28, 2026.
• A further 487 Restricted Stock Units, categorized as 'Premium', were also acquired, vesting on May 29, 2026.
• In total, Mr. Chiminski acquired 9,755 restricted stock units, all reported with a transaction price of $0 as they represent grants or conversions in lieu of cash.
• All reported securities are beneficially owned directly by Mr. Chiminski.

Sentiment

Score: 7

Explanation: The sentiment is positive as the director is increasing their equity stake in the company through compensation, which aligns their interests with shareholders. This is a routine and generally favorable disclosure.

Positives

• The acquisition of restricted stock units by a director aligns management's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Receiving equity in lieu of cash payments for Board services demonstrates a commitment to the company's long-term success and capital preservation.

Future Outlook

The future outlook for the reporting person's equity holdings includes the vesting of 6,829 restricted stock units on May 29, 2026, and 487 restricted stock units on May 29, 2026. Additionally, 610 shares of converted restricted stock units will vest on August 29, 2025, another 610 shares on November 29, 2025, and a final 610 shares on February 28, 2026.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to equity compensation for a non-employee director. It reflects standard corporate governance practices where directors receive a portion of their compensation in company stock or stock equivalents to align their financial interests with those of the shareholders. This practice is common across various industries, including the diagnostics and medical device sector where QuidelOrtho operates.

Comparison to Industry Standards

• The practice of compensating non-employee directors with restricted stock units (RSUs) is a common and widely accepted corporate governance standard across most publicly traded companies, including those in the healthcare and diagnostics industry like QuidelOrtho.
• The conversion of cash compensation into equity (RSUs) is also a standard mechanism for deferred compensation plans for directors, aiming to further align their long-term interests with shareholder value creation, similar to practices seen in companies like Abbott Laboratories (ABT) or Danaher Corporation (DHR) which also operate in related life sciences and diagnostics fields.

Related Party Transactions

• The acquisition of 2,439 restricted stock units in lieu of cash payments for retainer and Board of Director service-related fees represents a transaction between the company and a related party (a director), which is part of a standard deferred compensation program for non-employee directors.

Stakeholder Impact

• Shareholders: The director's increased equity ownership aligns their financial incentives with shareholder value creation, potentially leading to decisions that benefit long-term stock performance.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Vesting of 610 converted restricted stock units on August 29, 2025.
• Vesting of 610 converted restricted stock units on November 29, 2025.
• Vesting of 610 converted restricted stock units on February 28, 2026.
• Vesting of 6,829 equity grant restricted stock units on May 29, 2026.
• Vesting of 487 premium restricted stock units on May 29, 2026.

Key Dates

Keywords

QuidelOrtho, QDEL, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation, Director Compensation, Corporate Governance